文献速递肾小球疾病血液净化与透析

欧洲原发性肾小球疾病致终末期肾病肾脏替代治疗发病率与结局

Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

标化发病率为16.6/百万人口,各国差异大,IgA肾病和局灶节段性肾小球硬化发病率最高且呈上升趋势;新月体性肾小球肾炎死亡风险最高,心血管疾病为最常见死因。

要点

  • 原发性肾小球疾病致终末期肾病肾脏替代治疗标化发病率为16.6/百万人口,各国差异显著。
  • IgA肾病和局灶节段性肾小球硬化发病率最高且呈上升趋势。
  • 新月体性肾小球肾炎死亡风险最高,心血管疾病为最常见死因。

核心结论

  • 原发性肾小球疾病致终末期肾病肾脏替代治疗发病率各国差异大,IgA肾病和局灶节段性肾小球硬化最高且上升。
  • 部分国家缺乏肾活检可能影响终末期肾病病因的准确判定。
  • 识别不同原发性肾小球疾病亚组的发病率和结局有助于个体化患者管理。

研究设计与样本

  • 基于欧洲肾脏协会登记系统的回顾性队列研究。
  • 使用ERA原发肾病编码定义六个原发性肾小球疾病亚组。
  • 分析年龄和性别标化发病率、发病率趋势及生存。

主要发现

  • 原发性肾小球疾病致终末期肾病肾脏替代治疗标化发病率为16.6/百万人口,范围从塞尔维亚8.6/百万人口到法国20.0/百万人口。
  • IgA肾病和局灶节段性肾小球硬化发病率最高,分别为4.6/百万人口和2.6/百万人口。
  • 未行组织学检查的原发性肾小球疾病在塞尔维亚、波斯尼亚和黑塞哥维那、罗马尼亚占50%以上,在希腊、爱沙尼亚、比利时和瑞典也常见。
  • 发病率从2000年18.6/百万人口降至2013年14.5/百万人口,之后稳定。
  • 所有原发性肾小球疾病亚组5年生存率均高于50%,新月体性肾小球肾炎死亡风险最高(校正风险比1.8,95%CI 1.6-1.9,以IgA肾病为参照)。

临床怎么用

  • 应关注IgA肾病和局灶节段性肾小球硬化所致终末期肾病肾脏替代治疗发病率的上升趋势。
  • 新月体性肾小球肾炎患者透析起始后死亡风险较高,需加强监测与管理。
  • 心血管疾病为最常见死因,提示需重视肾脏替代治疗患者的心血管风险管理。
  • 肾活检设施不足可能影响终末期肾病病因判定,应加强病理诊断能力。

局限性

  • 部分国家缺乏肾活检设施可能影响终末期肾病病因的准确判定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary glomerular disease (PGD) is a major cause of end-stage kidney disease (ESKD) leading to kidney replacement therapy (KRT). We aimed to describe incidence (trends) in individuals starting KRT for ESKD due to PGD and to examine their survival and causes of death. METHODS: We used data from the European Renal Association (ERA) Registry on 69 854 patients who started KRT for ESKD due to PGD between 2000 and 2019. ERA primary renal disease codes were used to define six PGD subgroups. We examined age and sex standardized incidence, trend of the incidence and survival. RESULTS: The standardized incidence of KRT for ESKD due to PGD was 16.6 per million population (pmp), ranging from 8.6 pmp in Serbia to 20.0 pmp in France. Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) had the highest incidences, of 4.6 pmp and 2.6 pmp, respectively. Histologically non-examined PGDs represented over 50% of cases in Serbia, Bosnia and Herzegovina, and Romania and were also common in Greece, Estonia, Belgium and Sweden. The incidence declined from 18.6 pmp in 2000 to 14.5 pmp in 2013, after which it stabilized. All PGD subgroups had 5-year survival probabilities above 50%, with crescentic glomerulonephritis having the highest risk of death [adjusted hazard ratio 1.8 (95% confidence interval 1.6-1.9)] compared with IgAN. Cardiovascular disease was the most common cause of death (33.9%). CONCLUSION: The incidence of KRT for ESKD due to PGD showed large differences between countries and was highest and increasing for IgAN and FSGS. Lack of kidney biopsy facilities in some countries may have affected accurate assignment of the cause of ESKD. The recognition of the incidence and outcomes of KRT among different PGD subgroups may contribute to a more individualized patient care approach.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Abd ElHafeez S, Kramer A, Arici M, et al. Incidence and outcomes of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease in Europe: findings from the ERA Registry. Nephrol Dial Transplant. 2024. PMID: 38327216. doi:10.1093/ndt/gfae034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。